A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
According to the Constitution of Venezuela, in the event of the president becoming permanently unavailable to serve, a new election must be held within 30 days; in the event of them becoming temporarily unable to serve, the vice president acts as president for up to 90 days, which can be extended by vote of the National Assembly. The Supreme Court ruled that his absence was temporary, not permanent. Nicolás Maduro Guerra, Venezuelan congressman and son of Nicolás Maduro, declared on 27 January 2026 that elections in Venezuela are "not on the table" as his father was "kidnapped". On the US Senate hearing on 28 January, US secretary of state Marco Rubio was questioned about Venezuela. When discussing the goal of the intervention he answered "What's the end state? We want a Venezuela that has legitimate democratic elections." In an interview for Politico in February, Machado said that she had not spoken with Trump about elections in Venezuela, but she estimated that with manual voting an election could be held in 9 to 10 months. In an interview for Newsmax, Jorge Rodríguez ruled out elections in the short term, stating "The only thing I can say is that there will be no elections in this immediate period in which stabilization must be achieved." On 24 July, U.S. President Trump said that Venezuela was not ready to hold elections, but that it was making a lot of progress under acting President Rodriguez who has "been doing a fantastic job".
Bird said he was not trying to sabotage Clark's effort. He said he merely had told several witnesses for the state that "I don't think you should jeopardize your reputation with the way [the trial] is being handled." Clark stated he was considering legal action against Bird, whose actions, he said, were "tantamount to tampering with justice."
=== Gelling agents === Gelling agents are food additives used to thicken and stabilize various foods, like jellies, desserts and candies. The agents provide the foods with texture through formation of a gel. Some stabilizers and thickening agents are gelling agents. Typical gelling agents are based on polysaccharides such as natural gums, starches, pectins and agar-agar or proteins such as gelatin. Examples are:
==== Established in the first team ==== Now back at Tottenham, Townsend started the second Premier League match of their 2013–14 season, and went on to make a total of 33 appearances, including 25 in the league. He scored twice, in a 5–0 away victory over Dinamo Tbilisi in the Europa League (his first match of the season), and his first in the Premier League in a 2–0 victory away to Aston Villa on 20 October 2013. In the middle of the season, Townsend came under the management of his third Tottenham boss, after Villas-Boas was replaced by Tim Sherwood. Sherwood's contract was terminated at the end of the season, and Townsend started the 2014–15 season under new manager Mauricio Pochettino. He made a total of 35 appearances, scoring five goals, but was reduced to just 17 appearances in the league, having been unable to hold down a starting place until the second half of the season. He started as Tottenham lost 2–0 to Chelsea in the 2015 League Cup Final at Wembley Stadium on 1 March. Having had nine loan spells, Townsend's career path to regular first team football for Tottenham is often discussed in the context of a wider debate in English football about the best way to develop young talent, contrasting the loan route with Premier League players being developed in Under-21 leagues, or being brought to the Premier League level via transfers from lower league clubs.
Necrobiosis Lipoidica is a rare, chronic skin condition predominantly associated with diabetes mellitus (known as necrobiosis lipoidica diabeticorum or NLD). It can occur in individuals with rheumatoid arthritis or without any underlying conditions (idiopathic). It can also occur in patients with obesity, hypertension, celiac disease, and metabolic syndrome. Approximately a quarter of Necrobiosis Lipoidica cases are associated with diabetes mellitus. The broader overarching definition of necrobiosis is a gradual physiological death of a cell. It can be caused by basophilia, erythema, or a tumor. As a dermapathology term, it refers to altered collagen or altered dermal connective tissue. Necrobiosis Lipoidica is linked to microvascular damage and collagen degeneration. The exact cause of this condition is not known. It involves collagen degeneration and a granulomatous response in the layer of the skin called the dermis, often affecting the deeper fat layer and thickening dermal blood vessels. It is characterized by hardened, raised areas of the skin, often appearing on the shins, with a yellowish center and a surrounding dark pink area. The lesions are generally asymptomatic but can become tender and ulcerate when injured. Histological features and skin changes are caused by thickening of the blood vessel wall, collagen deterioration, granuloma (clustered white blood cells in tissues) formation, and fat deposits. Necrobiosis Lipoidica has many possible contributing factors, and research for treatment and causes is an ongoing process.
Sources: en.wikipedia.org
== Medical uses == Lemborexant is used in the treatment of insomnia in adults. A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that lemborexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.36 (95% CITooltip confidence interval 0.08 to 0.63) and at 3 months of 0.41 (95% CI 0.04 to 0.78). Lemborexant had similar effect sizes at 4 weeks as the other evaluated and marketed orexin receptor antagonists suvorexant (SMD 0.31, 95% CI 0.01 to 0.62) and daridorexant (SMD 0.23, 95% CI –0.01 to 0.48), whereas benzodiazepines and Z-drugs generally showed larger effect sizes (e.g., SMDs of 0.45 to 0.83) than lemborexant and the other orexin receptor antagonists. However, the review concluded that lemborexant and eszopiclone among all of the insomnia medications assessed had the best profiles overall in terms of efficacy, tolerability, and acceptability. Compared to benzodiazepines, there is a low risk of developing tolerance and dependence. Memory and attention are not affected the next morning when taking lemborexant.
==== European investigations ==== In 2000 a study to address the concerns regarding cardiovascular safety was requested by the EMA, and the makers agreed to perform post-marketing a long-term cardiovascular morbidity/mortality study in patients on rosiglitazone in combination with a sulfonylurea or metformin: the RECORD study. The results as published in 2009 showed non-inferiority with regard to cardiovascular events and cardiovascular death when the treatment with rosiglitazone was compared with metformin or a sulfonylurea. For myocardial infarction, there was a non-statistically significant increase in risk. In their assessment, the European regulators acknowledged weaknesses of the study, such as an unexpectedly low rate of cardiovascular events and the open-label design, which may lead to reporting bias. They found that the results were inconclusive. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market. According to a probe by the British Medical Journal in September 2010, the United Kingdom's Commission on Human Medicines recommended to the Medicines and Healthcare Products Regulatory Agency (MHRA) back in July 2010, to withdraw Avandia sale because its "risks outweigh its benefits". Additionally, the probe revealed that in 2000, members of the European panel in charge of reviewing Avandia prior to its approval had concerns about the long-term risks of the drug.
==== Ferrous iron uptake via protein transporters in land plants and chlorophytes ==== Distant homologues of the metal ion transporters ZIP in land plants and chlorophytes have converged in structure, likely to take up Fe2+ efficiently. The IRT1 proteins from Arabidopsis thaliana and rice have extremely different amino acid sequences from Chlamydomonas's IRT1, but their three-dimensional structures are similar, suggesting convergent evolution.
p A + q B ⇌ ApBq The study of these complexes is important for supramolecular chemistry and molecular recognition. The objective of these studies is often to find systems with a high binding selectivity of a host (receptor) for a particular target molecule or ion, the guest or ligand. An application is the development of chemical sensors. Finding a drug which either blocks a receptor, an antagonist which forms a strong complex the receptor, or activate it, an agonist, is an important pathway to drug discovery.
"Adequate calcium and regular exercise may help achieve strong bones in children and adolescents and reduce the risk of osteoporosis in older adults. An adequate intake of vitamin D is also necessary." Japan: Foods with Nutrient Function Claims (FNFC)
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.